The interplay between N6-methyladenosine and precancerous liver disease: molecular functions and mechanisms

Zhihua Lv; Ruoxi Ran; Yuting Yang; Meixian Xiang; Hanwen Su; Jingtao Huang

doi:10.1007/s12672-023-00695-2

The interplay between N6-methyladenosine and precancerous liver disease: molecular functions and mechanisms

Discov Oncol. 2023 May 25;14(1):78. doi: 10.1007/s12672-023-00695-2.

Authors

Zhihua Lv^#¹, Ruoxi Ran^#¹, Yuting Yang^#², Meixian Xiang³, Hanwen Su¹, Jingtao Huang⁴

Affiliations

¹ Department of Clinical Laboratory, Institute of Translational Medcine, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
² Department of General Office, School of Stomatology, Wuhan University, Wuhan, China.
³ School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, China.
⁴ Department of Clinical Laboratory, Institute of Translational Medcine, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China. jthuang@whu.edu.cn.

^# Contributed equally.

Abstract

N6-methyladenosine(m⁶A) is one of the most abundant modifications of mammalian cellular RNAs. m⁶A regulates various biological functions in epitranscriptomic ways, including RNA stability, decay, splicing, translation and nuclear export. Recent studies have indicated the growing importance of m⁶A modification in precancerous disease, influencing viral replication, immune escape, and carcinogenesis. Here, we review the role of m⁶A modification in HBV/HCV infection, NAFLD and liver fibrosis, and its function in liver disease pathogenesis. Our review will provide a new sight for the innovative treatment strategy for precancerous liver disease.

Keywords: Carcinogenesis; Liver disease; Molecular mechanisms; m6A.

Publication types

Review

Abstract

Publication types

Grants and funding